Management ChangeJul 13, 2026, 04:17 PM
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team
AI Summary
Eupraxia Pharmaceuticals announced significant changes to its executive leadership team to support its next phase of clinical and commercial development. Dr. Jeff Millard joined as Executive Vice President, Technical Operations, bringing extensive experience in CMC and regulatory strategy. Dr. Alex Therien will now lead Research & Development as Executive Vice President, R&D. Additionally, Amanda Malone stepped down from her role, and the company is transitioning its operations to Vancouver and Seattle, with key executives based in Seattle.
Key Highlights
- Dr. Jeff Millard appointed Executive Vice President, Technical Operations, effective July 13, 2026.
- Dr. Alex Therien to lead Research & Development as Executive Vice President, R&D.
- Amanda Malone stepped down as Chief Scientific and Operating Officer, effective July 10, 2026.
- Company transitioning operations from Victoria to Vancouver and Seattle.
- Key executive leadership, including the CEO, will be based in Seattle offices.
Price Impact
More from EPRX